Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentre Double Blind Randomized Clinical Study Evaluating The Efficacy and Safety of BCD-021 (CJSC BIOCAD, Russia) and Lucentis® (Novartis Pharmaceuticals Canada Inc.) in Patients With Neovascular Wet Age-related Macular Degeneration

NCT02036723 is registered in ClinicalTrials.gov with Biocad as lead sponsor.

NCT NCT02036723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02036723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentre Double Blind Randomized Clinical Study Evaluating The Efficacy and Safety of BCD-021 (CJSC BIOCAD, Russia) and Lucentis® (Novartis Pharmaceuticals Canada Inc.) in Patients With Neovascular Wet Age-related Macular Degeneration
Lead sponsor
Biocad
Phase
Phase 3
Overall status
Withdrawn
Start date
Not reported
Completion date
Not reported
Enrollment
0 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

wet age-related macular degeneration